Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC

Prior treatment

• Patients who have received other immunotherapy within 1 month (such as immunotherapy with checkpoint inhibitors, therapeutic antibodies, immune cell therapy, and immune system modulator therapy);
• The patient is affected by drug abuse, clinical or psychological or social factors that make informed consent or research implementation affected;

Other illness

• The patient has HIV infection, HBV infection, HCV infection, uncontrolled coronary artery disease or asthma, uncontrolled cerebrovascular disease, or other disease that the investigator considers ineligible;
• Patients with a history of bone marrow or organ transplantation;
• People with coagulation disorders;
• Gastrointestinal bleeding or gastrointestinal bleeding tendency;
• Subjects with immune deficiency diseases or autoimmune diseases;
• People who may be allergic to immunotherapy;

Other

• Pregnant and lactating women;
• Patients who are participating in or have participated in other clinical trials within 1 month;
• Any uncertainty affecting the patient's safety or compliance.

• Patients with stage II, III, and IV epithelial ovarian cancer who can be surgically resected and can provide sufficient tumor tissue samples, including paraffin-embedded (FFPE) blocks or fresh sections of formalin-fixed tissue within six months (approved by the organizer only);
• 18-70 years old;
• In the judgment of the researcher, be able to comply with the research protocol;
• Voluntarily join the study and sign the informed consent;
• Patients should meet the following hematological indicators: neutrophil count ≥1.5×109 /L; Hemoglobin ≥10.0 g/dL; Platelet count ≥100×109 /L; Total bilirubin ≤2× upper limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2× upper limit of normal value (ULN); Creatinine clearance ≥60 ml/min;
• Expected survival ≥ 3 months;
• The performance status of the Eastern Cancer Cooperation Group (ECOG) was 0 or 1.
• Postoperative ctDNA MRD test was positive, routine blood index was negative, imaging was negative.